CHROMADEX CORPORATION (NASDAQ:CDXC) Files An 8-K Other Events
Item 8.01
|
Other Events.
|
complaint (the Complaint) in the United States District Court for
the Central District of California, naming Elysium Health, Inc.
as defendant. Among other allegations, ChromaDex alleges in the
Complaint that (i) Elysium breached the Supply Agreement, dated
June 26, 2014, by and between ChromaDex and Elysium Health, LLC
(Elysium) (the pTeroPure Supply Agreement), by failing to make
payments to ChromaDex for purchases of pTeroPure pterostilbene
(pTeroPure) to the pTeroPure Supply Agreement, (ii) Elysium
breached the Supply Agreement, dated February 3, 2014, by and
between ChromaDex and Elysium, as amended (the NIAGEN Supply
Agreement), by failing to make payments to ChromaDex for
purchases of NIAGEN nicotinamide riboside (NIAGEN) to the NIAGEN
Supply Agreement, (iii) Elysium breached the Trademark License
and Royalty Agreement, dated February 3, 2014, by and between
ChromaDex and Elysium (the License Agreement), by failing to make
payments to ChromaDex for royalties due to the License Agreement
and (iv) certain officers of Elysium made false promises and
representations to induce ChromaDex into providing large supplies
of pTeroPure and NIAGEN to Elysium to the pTeroPure Supply
Agreement and NIAGEN Supply Agreement. ChromaDex is seeking
punitive damages, money damages and interest.
foregoing description is qualified in its entirety by reference
to the text of the Complaint and is incorporated herein by
reference and constitutes part of this report.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
Complaint, filed on December 29, 2016, by ChromaDex, Inc.
in the United States District Court for the Central District of California (exhibits have been omitted). |
About CHROMADEX CORPORATION (NASDAQ:CDXC)
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks. CHROMADEX CORPORATION (NASDAQ:CDXC) Recent Trading Information
CHROMADEX CORPORATION (NASDAQ:CDXC) closed its last trading session up +0.17 at 3.67 with 401,156 shares trading hands.
